CAMBRIDGE, Mass., May 01, 2017 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare
neuromuscular diseases, granted equity awards on April 28, 2017, that were previously approved by the Compensation Committee of its
Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to seven
individuals hired by Sarepta in April 2017. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase 21,317 shares of Sarepta's common stock. The options have an
exercise price of $36.26 per share, which is equal to the closing price of Sarepta's common stock on April 28, 2017. One-fourth of
the shares underlying each employee’s option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th
of the shares underlying each employee’s option will vest monthly, such that the shares underlying the option granted to each
employee will be fully vested on the fourth anniversary of his or her date of hire, in each case, subject to each such employee’s
continued employment with Sarepta on such vesting dates.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of unique
RNA-targeted therapeutics for the treatment of rare neuromuscular diseases. The Company is primarily focused on rapidly advancing
the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information,
please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website
at www.sarepta.com. We encourage investors and potential investors to consult our website
regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan, 617-274-4052 iestepan@sarepta.com or W2O Group Brian Reid, 212-257-6725 breid@w2ogroup.com
